G-Protein-Coupled Receptor Kinase 4 Polymorphisms and Blood Pressure and Response to Candesartan Among Southwestern Han Chinese With Essential Hypertension
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Third Military Medical University.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
Yu Changqing, Third Military Medical University
First received: June 24, 2012
Last updated: June 26, 2012
Last verified: June 2012
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
Mild to Moderate Essential Hypertension
||Observational Model: Case Control
Time Perspective: Cross-Sectional
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||July 2012 (Final data collection date for primary outcome measure)
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.
|Ages Eligible for Study:
||30 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
men and women with mild to moderate essential hypertension in southwestern Han Chinese
- men and women with mild to moderate essential hypertension in southwestern Han Chinese
- subjects unwilling to participate or subjects did not have all measurement required,
- subjects who were on medications, which affect blood pressure or
- whose DNA failed to amplify and 8 with errors in Mendelian segregation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01629225
Third Military Medical University
No publications provided
||Yu Changqing, Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;, Third Military Medical University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 24, 2012
||June 26, 2012
||China: Food and Drug Administration
Keywords provided by Third Military Medical University:
men and women
in southwestern Han Chinese
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 22, 2014
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action